Webinar:  CLIA IQCP: Difference from Standard QC Approach, Requirements and Laboratory Compliance


AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com.

AstraZeneca RSS Channel

Title Filter      Display #  
# Article Title
1 United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
2 AstraZeneca agrees strategic transaction with Almirall in respiratory disease
3 MedImmune and Advaxis partner on immuno-oncology combination clinical trial
4 AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
5 AstraZeneca and Max Planck Institute announce research agreement
6 AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
7 Clarification regarding Pfizer statement
8 MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial
9 AstraZeneca Board rejects Pfizer proposal
10 AstraZeneca and MRC enter strategic collaboration
11 MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
12 FDA Advisory Committee votes on investigational medicine metreleptin
13 AstraZeneca to invest £120 million in new manufacturing facility to produce Zoladex
14 AstraZeneca advances MedImmune's benralizumab to Phase III in severe asthma
15 AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
16 AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
17 AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
18 MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
19 AstraZeneca PLC second quarter and half year results 2013
20 AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]